Mannan peptide tablets

Pharmacological action: Pharmacological experiments have shown that it can inhibit the synthesis of DNA and RNA and glucose metabolism of cell lines such as S-180 sarcoma, Ehrlich ascites carcinoma and human tongue squamous cell carcinoma Tca8113 in vitro; it can inhibit the growth of Ehrlich ascites carcinoma, S-180 sarcoma and HePA liver cancer ascites tumor in vivo (tumor inhibition rate 63%), can increase peripheral leukocytes, enhance the phagocytic function of the reticuloendothelial system, activate macrophages and lymphocytes, induce thymus lymphocytes to produce active substances, improve and enhance the body's immune function and stress capacity. After being injected into the human body, this product has the effect of activating phagocytes, NK cells, and T.B cell subsets; it has the effect of inducing interferon and interleukin. It can cause chromosomes of tumor cells, viruses, etc. to break and cause apoptosis, and can induce a variety of effector cells and cytokines to produce a "cytokine cocktail" effect, broad-spectrum killing of viruses and pathogens, and broad-spectrum induction of tumor cell apoptosis. Non-clinical toxicology study: This product has no carcinogenicity, reproductive toxicity, genetic toxicity and long-term toxicity. The Bliss method was used for intravenous injection into Kunming mice, with a single dose of 675.3-4018.0 mg/kg. After seven days of observation, the LD50 was measured to be 1707.0 mg/kg. The Kunming mice were injected intraperitoneally, with a single dose of 6097.5-11687.5 mg/kg. After seven days of observation, the LD50 was measured to be 8041.2 mg/kg.

α-Mannan peptide

This product is off-white tablet.

Used as an adjuvant treatment for immunosuppression, recurrent respiratory tract infections, leukopenia, aplastic anemia and tumor treatment, and to reduce the side effects of radiotherapy and chemotherapy on the hematopoietic system and gastrointestinal reactions.

Oral administration, 5-10 mg (1-2 tablets) at a time, 3 times a day, one course of treatment per month. For children, the dosage should be reduced or as directed by the doctor.

A small number of patients have transient fever and occasional rash.

1. Patients with rheumatic heart disease are prohibited from using this product. 2. Patients who are allergic to this product are prohibited from using this product.

Not yet clear.

Keep tightly closed in a cool, dry place.

5mg

Liaoning Xingao Pharmaceutical Co., Ltd.

• Founded in:

  2009-01-07

• Address:

  No. 8 Xiangzhang Road, Shiqiaozi, Xihu District, Benxi City

• Tax NO.:

  91210500683709405F

• Registered Funds:

  50 million yuan

• Email:

  Log in to view